{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:00:41Z","timestamp":1769018441429,"version":"3.49.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T00:00:00Z","timestamp":1628553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"National Institutes of Health, National Institute of Allergy and Infectious Disease","award":["AI111891"],"award-info":[{"award-number":["AI111891"]}]},{"DOI":"10.13039\/100011072","name":"University of North Carolina at Chapel Hill Center for AIDS Research","doi-asserted-by":"crossref","award":["P30 AI50410"],"award-info":[{"award-number":["P30 AI50410"]}],"id":[{"id":"10.13039\/100011072","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007862","name":"California National Primate Research Center","doi-asserted-by":"publisher","award":["OD011107"],"award-info":[{"award-number":["OD011107"]}],"id":[{"id":"10.13039\/100007862","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Investigating antiretroviral (ARV) penetration and pharmacology in lymph nodes is crucial to understanding mechanisms of HIV persistence in tissue, but sampling these tissues in humans is invasive and costly. Physiologically based pharmacokinetic (PBPK) modelling is a non-invasive solution for understanding lymph node penetration of ARVs across multiple species.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To develop customized PBPK models with a novel lymph node compartment, and use these models to describe the distribution of three ARVs\u2014tenofovir, emtricitabine and efavirenz\u2014into the plasma and lymph nodes of non-human primates (NHPs) and humans.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and methods<\/jats:title>\n                  <jats:p>In this analysis, we utilized standard monkey and human PBPK models in PK-Sim, and added a novel lymph node compartment using MoBi. We used these models to describe the distribution of tenofovir, emtricitabine and efavirenz into NHP and human plasma and lymph nodes, and compared model-predicted versus observed AUC and Cmax.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>For all three ARVs, population simulations using the base and final models reasonably characterized observed plasma and tissue data in NHPs and humans, with predicted\/observed AUC and Cmax ratios within 0.7\u20132.0.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Overall, our novel PBPK model provides a framework for understanding lymph node penetration of ARVs or future HIV cure therapies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkab298","type":"journal-article","created":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T19:22:44Z","timestamp":1627586564000},"page":"2890-2893","source":"Crossref","is-referenced-by-count":2,"title":["A cross-species comparison of antiretroviral penetration into lymph nodes using novel physiologically based pharmacokinetic models"],"prefix":"10.1093","volume":"76","author":[{"given":"Erin M B","family":"Scholz","sequence":"first","affiliation":[{"name":"Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, 301 Pharmacy Lane, Chapel Hill, NC 27599, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanguang","family":"Cao","sequence":"additional","affiliation":[{"name":"Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, 301 Pharmacy Lane, Chapel Hill, NC 27599, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela D M","family":"Kashuba","sequence":"additional","affiliation":[{"name":"Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, 301 Pharmacy Lane, Chapel Hill, NC 27599, USA"},{"name":"School of Medicine, University of North Carolina at Chapel Hill, 321 S Columbia Street, Chapel Hill, NC 27516, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,8,10]]},"reference":[{"key":"2022012214310614600_dkab298-B1","doi-asserted-by":"crossref","first-page":"ofx173","DOI":"10.1093\/ofid\/ofx173","article-title":"Ongoing HIV replication during ART reconsidered","volume":"4","author":"Kearney","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2022012214310614600_dkab298-B2","doi-asserted-by":"crossref","first-page":"4629","DOI":"10.1172\/JCI126714","article-title":"HIV-1 in lymph nodes is maintained by cellular proliferation during antiretroviral therapy","volume":"129","author":"McManus","year":"2019","journal-title":"J Clin Invest"},{"key":"2022012214310614600_dkab298-B3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nature16933","article-title":"Persistent HIV-1 replication maintains the tissue reservoir during therapy","volume":"530","author":"Lorenzo-Redondo","year":"2016","journal-title":"Nature"},{"key":"2022012214310614600_dkab298-B4","doi-asserted-by":"crossref","first-page":"8984","DOI":"10.1128\/JVI.00684-16","article-title":"HIV maintains an evolving and dispersed population in multiple tissues during suppressive combined antiretroviral therapy in individuals with cancer","volume":"90","author":"Rose","year":"2016","journal-title":"J Virol"},{"key":"2022012214310614600_dkab298-B5","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1124\/jpet.119.259150","article-title":"Antiretroviral drug concentrations in lymph nodes: a cross-species comparison of the effect of drug transporter expression, viral infection, and sex in humanized mice, nonhuman primates, and humans","volume":"370","author":"Burgunder","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"2022012214310614600_dkab298-B6","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/psp4.12150","article-title":"p16INK4a, a senescence marker, influences tenofovir\/emtricitabine metabolite disposition in HIV-infected subjects","volume":"6","author":"Dumond","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2022012214310614600_dkab298-B7","first-page":"262","article-title":"Considerations in the development of nonhuman primate models of combination antiretroviral therapy for studies of AIDS virus suppression, residual virus, and curative strategies","volume":"8","author":"Del Prete","year":"2013","journal-title":"Curr Opin HIV AIDS"},{"key":"2022012214310614600_dkab298-B8","doi-asserted-by":"crossref","first-page":"7349","DOI":"10.1128\/JVI.79.12.7349-7354.2005","article-title":"Suppression of virus load by highly active antiretroviral therapy in rhesus macaques infected with a recombinant simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1","volume":"79","author":"North","year":"2005","journal-title":"J Virol"},{"key":"2022012214310614600_dkab298-B9","doi-asserted-by":"crossref","first-page":"5324","DOI":"10.1128\/JVI.78.10.5324-5337.2004","article-title":"CD8+-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment","volume":"78","author":"Van Rompay","year":"2004","journal-title":"J Virol"},{"key":"2022012214310614600_dkab298-B10","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/psp4.12151","article-title":"Population pharmacokinetics modeling of unbound efavirenz, atazanavir, and ritonavir in HIV-infected subjects with aging biomarkers","volume":"6","author":"Dumond","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2022012214310614600_dkab298-B11","first-page":"85\u2013265","article-title":"Basic anatomical and physiological data for use in radiological protection: reference values","volume":"32","year":"2002","journal-title":"Ann ICRP"},{"key":"2022012214310614600_dkab298-B12","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/psp4.12338","article-title":"Physiologically based pharmacokinetic approach to determine dosing on extracorporeal life support: fluconazole in children on ECMO","volume":"7","author":"Watt","year":"2018","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2022012214310614600_dkab298-B13"},{"key":"2022012214310614600_dkab298-B14"},{"key":"2022012214310614600_dkab298-B15"},{"key":"2022012214310614600_dkab298-B16","year":"2017"},{"key":"2022012214310614600_dkab298-B17"},{"key":"2022012214310614600_dkab298-B18","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.tiv.2007.09.010","article-title":"General approach for the calculation of tissue to plasma partition coefficients","volume":"22","author":"Schmitt","year":"2008","journal-title":"Toxicol in Vitro"},{"key":"2022012214310614600_dkab298-B19","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/jps.10005","article-title":"Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution","volume":"91","author":"Poulin","year":"2002","journal-title":"J Pharm Sci"},{"key":"2022012214310614600_dkab298-B20","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1007\/s11095-006-9210-3","article-title":"Mechanistic approaches to volume of distribution predictions: understanding the processes","volume":"24","author":"Rodgers","year":"2007","journal-title":"Pharm Res"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/76\/11\/2890\/42260088\/dkab298.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/76\/11\/2890\/42260088\/dkab298.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,22]],"date-time":"2022-01-22T14:31:28Z","timestamp":1642861888000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/76\/11\/2890\/6347333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,10]]},"references-count":20,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,8,10]]},"published-print":{"date-parts":[[2021,10,11]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkab298","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2021,8,10]]}}}